Biotech & Pharma

mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).

Leadership read: mbiomics's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across EMEA.

curated · 2026-10-16 · context →

Gilead is reportedly turning to an executive from BeOne to support its China expansion, signalling a push into the Chinese market.

Leadership read: Gilead Sciences's expansion resets where the leadership need sits in Biotech & Pharma. Standing up a new market rewards operators with local networks and a record of building from scratch. The 12-to-18-month read across Asia favours country and commercial leadership hired close to the ground.

curated · 2026-10-09 · context →

Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.

Leadership read: Market entry is a leadership problem before it is a logistics one. Bio-Techne moving into new ground in Biotech & Pharma deepens demand for in-region leaders who can localise the model without diluting it. Across EMEA, watch whether senior in-market leadership is appointed early; expansions run remotely rarely hold.

curated · 2026-10-08 · context →

AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.

Leadership read: A product move like this reshapes AviadoBio's org chart as much as its roadmap. Scaling in Biotech & Pharma rests on product leadership that can carry a launch to adoption and commercial hires who turn early traction into pipeline. The EMEA tell is whether senior GTM appointments follow; unsupported launches stall.

curated · 2026-10-08 · context →

bioAffinity Technologies raised approximately $4 million through registered direct financing and concurrent private placement priced at-the-market under Nasdaq rules.

Leadership read: bioAffinity Technologies, Inc.'s raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-10-08 · context →

Lotte Biologics signed a manufacturing agreement with Alvotech to produce multiple antibody biosimilar drug substances at its Syracuse, New York facility, expanding its global manufacturing partnerships.

Leadership read: Alliances broaden the commercial surface, and the leadership need follows. Lotte Biologics's partnership in Biotech & Pharma widens demand for commercial and alliance leaders who turn an agreement into realised value. Across Americas, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.

curated · 2026-10-07 · context →

BD announces $19 billion U.S. investment partnership with government, including $3 billion for domestic medical manufacturing expansion

Leadership read: Market entry is a leadership problem before it is a logistics one. BD (Becton Dickinson) moving into new ground in Biotech & Pharma deepens demand for in-region leaders who can localise the model without diluting it. Across Americas, watch whether senior in-market leadership is appointed early; expansions run remotely rarely hold.

curated · 2026-10-07 · context →

Valion Bio names Thomas H. Jensen, CEO of Allarity Therapeutics, as board chair to advance Entolimod program for acute radiation syndrome following company transformation

Leadership read: A change at the top rarely stays at the top. Valion Bio Inc.'s move reshapes the layer beneath it in Biotech & Pharma as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-10-05 · context →

Biogen announced 52-week Phase 2 results for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating rapid and durable efficacy. Data supports potential first-in-class therapy positioning. Results presented at EADV 2026 Congress in Vienna. Ongoing Phase 2/3 AMETHYST study progressing.

Leadership read: A product move like this reshapes Biogen Inc.'s org chart as much as its roadmap. Scaling in Biotech & Pharma rests on product leadership that can carry a launch to adoption and commercial hires who turn early traction into pipeline. The EMEA tell is whether senior GTM appointments follow; unsupported launches stall.

curated · 2026-10-02 · context →

Thermo Fisher Scientific launched Gibco CHO-K1 Catalog Panel, a cGMP-ready suite of chemically defined, animal origin-free basal and feed media in liquid and dry powder formats for CHO-K1 cell line support in biologics and biosimilars production.

Leadership read: Thermo Fisher Scientific's launch shifts talent demand before revenue catches up. In Biotech & Pharma, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether Thermo Fisher Scientific backs it with senior go-to-market hires across Americas. That separates a platform move from a one-off.

curated · 2026-10-01 · context →

Boehringer Ingelheim announced Phase III trial success for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, achieving 13.1% average weight loss in obesity and type 2 diabetes patients. Results published in NEJM and presented at EASD conference.

Leadership read: A product move like this reshapes Boehringer Ingelheim's org chart as much as its roadmap. Scaling in Biotech & Pharma rests on product leadership that can carry a launch to adoption and commercial hires who turn early traction into pipeline. The EMEA tell is whether senior GTM appointments follow; unsupported launches stall.

curated · 2026-10-01 · context →

Click Therapeutics, Inc. filed SEC Form D for private placement, indicating capital raising activity in therapeutics/digital health space.

Leadership read: Fresh capital is a hiring signal before it is anything else. For Click Therapeutics, Inc., a raise in Biotech & Pharma funds leadership depth, scale, go-to-market and operational rigour, rather than any single appointment. Watch where Click Therapeutics, Inc. hires first across Americas; that is where the capital is really pointed.

curated · 2026-10-01 · context →